CA2508581A1 - Spirocyclic ureas, compositions containing such compounds and methods of use - Google Patents

Spirocyclic ureas, compositions containing such compounds and methods of use Download PDF

Info

Publication number
CA2508581A1
CA2508581A1 CA002508581A CA2508581A CA2508581A1 CA 2508581 A1 CA2508581 A1 CA 2508581A1 CA 002508581 A CA002508581 A CA 002508581A CA 2508581 A CA2508581 A CA 2508581A CA 2508581 A1 CA2508581 A1 CA 2508581A1
Authority
CA
Canada
Prior art keywords
groups
optionally substituted
halo
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002508581A
Other languages
English (en)
French (fr)
Inventor
Emma R. Parmee
Fengqi Zhang
Dong-Ming Shen
John Stelmach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2508581A1 publication Critical patent/CA2508581A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002508581A 2002-12-04 2003-11-26 Spirocyclic ureas, compositions containing such compounds and methods of use Abandoned CA2508581A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43079902P 2002-12-04 2002-12-04
US60/430,799 2002-12-04
PCT/US2003/038590 WO2004050039A2 (en) 2002-12-04 2003-11-26 Spirocyclic ureas, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
CA2508581A1 true CA2508581A1 (en) 2004-06-17

Family

ID=32469534

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508581A Abandoned CA2508581A1 (en) 2002-12-04 2003-11-26 Spirocyclic ureas, compositions containing such compounds and methods of use

Country Status (6)

Country Link
US (1) US20060116366A1 (enExample)
EP (1) EP1569915A4 (enExample)
JP (1) JP2006509015A (enExample)
AU (1) AU2003298889A1 (enExample)
CA (1) CA2508581A1 (enExample)
WO (1) WO2004050039A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
SI1756064T1 (sl) * 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
DE602005017895D1 (de) * 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
AU2005269792B9 (en) 2004-07-22 2008-11-27 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
CA2615656A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2650619A1 (en) 2006-05-16 2007-11-29 Merck And Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8293759B2 (en) 2006-10-30 2012-10-23 Merck, Sharp & Dohme, Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2011119559A1 (en) * 2010-03-25 2011-09-29 Schering Corporation Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
JP2013523642A (ja) * 2010-03-26 2013-06-17 メルク・シャープ・エンド・ドーム・コーポレイション グルカゴン受容体拮抗薬としての新規なスピロイミダゾロン誘導体、組成物およびそれらの使用方法
JP2014040374A (ja) * 2010-12-15 2014-03-06 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
PH12013501557A1 (en) 2011-02-08 2019-06-03 Pfizer Glucagon receptor modulator
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
US8742111B1 (en) * 2013-02-21 2014-06-03 The United States Of America As Represented By The Secretary Of The Army Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
JP7155102B2 (ja) * 2016-07-07 2022-10-18 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
WO2018015235A1 (en) * 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
WO2021078132A1 (en) * 2019-10-21 2021-04-29 Sironax Ltd Inhibitors of mtor-mediated induction of autophagy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
FR2677984B1 (fr) * 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
DE4201709A1 (de) * 1992-01-23 1993-07-29 Bayer Ag (alpha)-aryl-(alpha)-hydroxy-ss-imidazolinyl-propionsaeureamide
KR19990012061A (ko) * 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
US6384061B1 (en) * 1997-07-26 2002-05-07 Lg Chemical Ltd. Hydantoin compounds and methods related thereto

Also Published As

Publication number Publication date
JP2006509015A (ja) 2006-03-16
EP1569915A2 (en) 2005-09-07
AU2003298889A1 (en) 2004-06-23
WO2004050039A2 (en) 2004-06-17
US20060116366A1 (en) 2006-06-01
EP1569915A4 (en) 2007-07-11
WO2004050039A3 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
US7803951B2 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US20060116366A1 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
AU2004210127B2 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
US7649009B2 (en) Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7301036B2 (en) Cyclic guanidines, compositions containing such compounds and methods of use
AU2005269792B2 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
JP2006528687A (ja) ベンズイミダゾール、こうした化合物を含有する組成物および使用方法
AU2007229850A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2650619A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7563815B2 (en) Benzamidazoles, compositions containing such compounds and methods of use
JP2008516952A (ja) ヒスタミンｈ３受容体阻害剤、製造及び治療的使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued